Verona Pharma is looking odds on for a regulatory approval for its chronic obstructive pulmonary disease (COPD) therapy ensifentrine, after chalking up a second positive phase 3 trial. The Anglo ...

Verona Pharma is starting a pilot study of its inhaled respiratory diseases drug ensifentrine in patients hospitalised with COVID-19. The Anglo-American biotech is already developing ensifentrine ...

Fintel reports that on January 10, 2025, Roth MKM initiated coverage of Verona Pharma plc - Depositary Receipt () (NasdaqGM:VRNA) with a Buy recommendation. Analyst Price Forecast Suggests 5.90% ...

H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

A pivotal phase III trial of Ensifentrine for the maintenance treatment of COPD in China is ongoing. This study is being conducted by Verona's partner in Greater China, Nuance Pharma. Results from ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

Verona Pharma (NASDAQ:VRNA – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $60.00 price target ...

For further information please contact: Verona P Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique ...

Verona Pharma Option Volume And Open Interest ... The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease ...

If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines ...